Batavia At LBSP ATMP TechTalks
Eize De Boer showed us what it takes to realize a new facility for Batavia Biosciences designed for viral vector manufacturing to support developers on a global scale.
The multi-product facility is designed to support the late-stage clinical manufacturing and commercial manufacturing of vaccines and viral vector-based gene therapy and immune-oncology products. Batavia’s highly intensified manufacturing technology, HIP-Vax®, which utilizes fixed-bed bioreactors, will be the main platform, but also products manufactured using traditional mammalian cell suspension technologies up to 1000L scale can readily be delivered.
The facility is based on a modular design, with 6 production suites. On-site, state-of-the-art fill / finish capabilities ensure on-time delivery of drug product. Depending on virus / vector type the facility is expected to provide for several hundred million doses annually.
Related
Accelerating Viral Vector and Vaccine Development: Beware Of The Pitfalls of Scale-Up
Why is scale-up of viral vaccines and viral vector products for clinical phase testing so challenging? Here are 5 of the biggest pitfalls.
Adenovirus Vectors in Gene Therapy – Vaccine Development & Delivery Tools
Adenovirus vectors are vital to gene therapy, vaccine development, and cancer virotherapies. Learn more about these important delivery tools.
Taking your adenoviral vector product from R&D to the clinic
The road from R&D to final production of an adenoviral vector product is well trodden. Here is information to help you on your journey.
